Clinical Trial: Chinese Adults With Kidney Disease

U.S., April 14 -- ClinicalTrials.gov registry received information related to the study (NCT07522099) titled 'Chinese Adults With Kidney Disease' on Feb. 27.

Brief Summary: This is a Phase 2 study to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics of ADX-038 in adults with complement-mediated kidney diseases. The study will enroll Chinese adults with IgA nephropathy, complement 3 glomerulopathy (C3G) and immune complex mebranoproliferative glomerulonephritis (IC-MPGN). The study will evaluate ADX-038 administered alone (Part A) and in combination with telitacicept (Part B).

Study Start Date: July 23, 2026

Study Type: INTERVENTIONAL

Condition: Immunoglobulin A Nephropathy (IgAN) Complement 3 Glomerulopathy (C3G)...